Skip to content

Study · Non-randomized trial · n = 13 · 2002

4 results

GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy.

Imazio M, Bobbio M, Broglio F, Benso A, Podio V, Valetto MR, Bisi G, Ghigo E, Trevi GP

European journal of heart failure1 Mar 2002Cited by 15 (Europe PMC)

PMID11959048 (opens in a new tab)DOI10.1016/s1388-9842(01)00223-9 (opens in a new tab)PepBankPUB-11959048
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with severe dilated or ischemic cardiomyopathy, intravenous hexarelin induced a similar significant increase in GH levels in both groups.

    In plain wordsIn patients with weak hearts from dilated or ischemic cardiomyopathy, hexarelin raised growth hormone similarly in both groups.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH levels after hexarelin in dilated and ischemic cardiomyopathy
    Study

    n = 13

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · i.v.As given in this study (human).

    Source sentences

    Summary
    In dCMP and iCMP patients hexarelin induced a similar significant (P<0.05) increase in GH levels.
    1 context sentence
    Summary · context
    We studied the effect of intravenous hexarelin administration on growth hormone (GH) levels and left ventricular ejection fraction (LVEF) evaluated by radionuclide angiography in eight patients with dCMP (age 53.0+/-2.8, LVEF 16.7+/-2.1%) and five patients with iCMP (age 52.0+/-2.8 years, LVEF 22.6+/-2.1).
  2. 02HumanNon-randomized trialEfficacy outcome

    In eight patients with dilated cardiomyopathy, intravenous hexarelin did not change left ventricular ejection fraction.

    In plain wordsIn eight patients with dilated cardiomyopathy, hexarelin did not change the heart's pumping fraction.

    Peptide
    Hexarelin
    Outcome
    No significant changeLVEF in dilated cardiomyopathy
    Study

    n = 8

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · i.v.As given in this study (human).

    Measurements

    peak LVEF
    17.7%
    dilated cardiomyopathy

    Source sentences

    Summary
    while in dCMP LVEF was unchanged (peak LVEF 17.7+/-1.7, P=NS).
    1 context sentence
    Summary · context
    We studied the effect of intravenous hexarelin administration on growth hormone (GH) levels and left ventricular ejection fraction (LVEF) evaluated by radionuclide angiography in eight patients with dCMP (age 53.0+/-2.8, LVEF 16.7+/-2.1%) and five patients with iCMP (age 52.0+/-2.8 years, LVEF 22.6+/-2.1).
  3. 03HumanNon-randomized trialEfficacy outcome

    In five patients with ischemic cardiomyopathy, intravenous hexarelin increased left ventricular ejection fraction.

    In plain wordsIn five patients with ischemic cardiomyopathy, hexarelin raised the heart's pumping fraction.

    Peptide
    Hexarelin
    Outcome
    IncreaseLVEF in ischemic cardiomyopathy
    Study

    n = 5

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · i.v.As given in this study (human).

    Measurements

    peak LVEF
    26.2%
    ischemic cardiomyopathy

    Source sentences

    Summary
    In iCMP patients hexarelin induced a LVEF increase (peak LVEF 26.2+/-2.5%, P<0.05)
    1 context sentence
    Summary · context
    We studied the effect of intravenous hexarelin administration on growth hormone (GH) levels and left ventricular ejection fraction (LVEF) evaluated by radionuclide angiography in eight patients with dCMP (age 53.0+/-2.8, LVEF 16.7+/-2.1%) and five patients with iCMP (age 52.0+/-2.8 years, LVEF 22.6+/-2.1).
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with cardiomyopathy and in comparison groups, other hemodynamic parameters were unchanged after hexarelin.

    In plain wordsIn patients with cardiomyopathy and in comparison groups, other heart and blood flow measures did not change after hexarelin.

    Peptide
    Hexarelin
    Outcome
    No significant changeOther hemodynamic parameters
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · i.v.As given in this study (human).

    Source sentences

    Summary
    In all groups other hemodynamic parameters were unchanged.
    1 context sentence
    Summary · context
    We studied the effect of intravenous hexarelin administration on growth hormone (GH) levels and left ventricular ejection fraction (LVEF) evaluated by radionuclide angiography in eight patients with dCMP (age 53.0+/-2.8, LVEF 16.7+/-2.1%) and five patients with iCMP (age 52.0+/-2.8 years, LVEF 22.6+/-2.1).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.